INTRODUCTION
Multiple sclerosis (MS, MIM 126200) is an inflammatory, demyelinating disease of the central nervous system (CNS), thought to be mediated by an autoimmune process. It affects over 2 million individuals world-wide. The disease is characterized by mononuclear cell infiltration in the CNS associated with demyelination leading to a spectrum of symptoms and disability within affected individuals. MS is most common in young adults and affects women two to three times more frequently than men. Family and twin studies have long shown evidence for a strong genetic component underlying the etiology of MS. Until recently, the major histocompatibility complex (MHC) was the only universally accepted genetic locus associated with MS.
In 2007, we reported the first genome-wide association study (GWAS) for MS susceptibility. In this GWAS, we screened 931 trio families (an affected individual and both parents) with 334 923 single-nucleotide polymorphisms (SNPs) and followed-up 110 of the most promising associations in additional cases (n ¼ 2322), controls (n ¼ 5418) and trio families (n ¼ 609). This first-pass follow-up resulted in the identification of three strongly associated SNPs outside of the MHC, namely rs6897932 in the interleukin-7 receptor a gene (IL7RA) and both rs12722489 and rs2104286 within the interleukin-2 receptor a gene (IL2RA) (1) . These associations were replicated by a number of groups (2) (3) (4) (5) and further refined in subsequent analyses (6) . The GWAS also identified highly suggestive associations with variations in CLEC16A and CD58, both of which have subsequently been confirmed, along with other genes identified through additional MS GWAS and restricted follow-up efforts (e.g. TNFRSF1A, IRF8, CD6, TYK2, CD226 and CYB27B1) (7) (8) (9) (10) (11) (12) (13) (14) . These genes are now the focus of multiple ongoing studies to confirm and understand their potential involvement in MS susceptibility.
Statistically we would expect the pool of moderately significant GWAS results to be enriched for genuine associations. To more comprehensively test for additional MS-associated loci, we examined approximately 30 000 SNPs, whose initial association P-values were 0.10 in the original IMSGC GWAS, in an independent data set.
RESULTS
In Stage 1, we obtained genotype data on 30 915 SNPs in 1488 cases and 3710 controls. Following extensive quality control (QC), we were ultimately able to utilize 29 561 SNPs in 1343 cases and 3577 controls for association with MS. This data set gave us 80% maximum potential power to detect risk odds ratio (OR) of 1.25, accepting a type 1 error rate of 0.001 (Supplementary Material, Fig. S1 ) (15) . There were 85 SNPs, outside of the MHC (i.e. 29 -34 Mb on chromosome 6), demonstrating high levels of significance (P 0.001) ( Table 1) . Detailed analysis of SNPs within the broader MHC is the focus of a separate parallel project. As the SNPs selected for Stage 1 were chosen without consideration of linkage disequilibrium (LD), there are a number of SNPs with P-values 0.0001 that are in relatively strong LD with each other and therefore the significant SNPs do not represent 85 independent loci. As expected, there are a number of Stage 1 top hits in previously identified MS genes, including CLEC16A (1,7), CD58 (1, 8) , IRF8 (11) and MMEL1 (M.B., unpublished data). As is typically the case in replication studies, previous top hits have shifted ranking in subsequent follow-up experiments. Our study is no exception, as the association P-values with arguably the two most notable genes, IL2RA (rs2104286, P ¼ 1.89 Â 10
22
) and IL7RA (rs6897932, P ¼ 1.03 Â 10
), fall just below our arbitrary P-value cutoff (P , 1.0 Â 10
24
) for inclusion in Table 1 (see Supplementary Material, Table S1 for results of the remaining 29 447 SNPs analyzed in Stage 1).
Following our analysis of the Stage 1 follow-up, we choose a smaller subset of SNPs for further replication in an independent data set. The results of the 19 SNPs genotyped (Sequenom MassARRAY iPLEX) and analyzed for Stage 2 (20 SNPs were genotyped, with 1 failing QC) are presented in Table 2 . Eight of these SNPs demonstrated further replication (P 0.05, with consistent OR) in this independent data set. A combined analysis for these 19 SNPs using data from the original screen and both Stage 1 and Stage 2 included 931 Trios, 3507 cases and 8024 controls. Five SNPs meet a conservative estimate of genome-wide significance using a Bonferroni correction (P-value cutoff 1.49 Â 10 27 ) considering the 334 923 independent tests from the original GWAS screen (Table 2) . Furthermore, 4/5 SNPs were significant in each of the independent data sets. These four SNPs lie within or nearby KIF21B (on chromosome 1), TMEM39A (on chromosome 3), C16orf75 and PRM1 (both on chromosome 16). However, the two SNPs on chromosome 16 (rs12922090 and rs243315) near C16orf75 and PRM1 are in very strong LD (D 0 ¼ 0.99, r 2 ¼ 0.82). We also performed conditional logistic regression on these 19 SNPs conditioning on the HLA-DRB1
Ã 1501 tag (rs3135388); interestingly, the three SNPs (rs12922090, rs243315 and rs12927773) on chromosome 16 show slightly more significance in the HLA conditional analysis (Table 2) .
DISCUSSION
We find considerable evidence for several new MS susceptibility loci including KIF21B (rs12122721, combined P ¼
Â 10

210
, OR ¼ 0.82), TMEM39A (rs1132200, combined P ¼ 3.09 Â 10
28
, OR ¼ 0.80) and PRM1 (rs243315, combined P ¼ 1.07 Â 10
27
, OR ¼ 0.83), all of which have demonstrated moderate-to-strong significance in each stage of our analyses and furthermore meet genome-wide significance using a stringent Bonferroni correction.
We have successfully identified novel loci for MS through more detailed examination of results from a large firstgeneration GWAS. Interestingly, in the original GWAS, the SNPs in KIF21B, TMEM39A and PRM1, although relatively significant in the more powerful case/control analysis [Cochran -Mantel-Haenszel (CMH) P-value ranks between 0.3 and 4.2%], failed to rise to the top of the more limited family-based analysis [the most significant SNP (rs12122721) had a transmission disequilibrium test (TDT) P-value rank of 28.9%] (Tables 1 and 3 ). Furthermore, these SNPs were among the top P-values (CMH P-value ranks between 0.4 and 2.1%) in a recent meta-analysis of three GWASs (11) ( Table 3 ). These overall results clearly demonstrate that additional true susceptibility loci are likely to be buried beneath the top association results from GWAS (and even meta-analyses of GWAS), and subsequently overlooked in the rush to follow up the top hits. Testing only the 'top hits' is often the result of the limited availability of resources after conducting such a massive initial screening experiment. Our data suggest that it is imperative to perform a more comprehensive follow-up study in the pursuit of identifying all loci contributing to the genetic load for a given complex disease.
Furthermore, of the top Stage 1 results (P 0.001), the average original GWAS P-value ranking of these SNPs is approximately 40 000 for the CMH test (most significant SNP ranking 177, least significant SNP ranking 319 841) and approximately 69 000 for the TDT test (most significant SNP ranking194, least significant SNP ranking 308 800). Approximately one-third (29/85) of the most significant non-MHC SNPs in Stage 1 ( Table 1) had original GWAS P-values ,0.10 in both the TDT and CMH tests, with only two of these SNPs further replicating in Stage 2 (rs11583328 and rs10469900) ( Table 2 ). We extended this examination by ranking the three SNPs meeting genome-wide significance (i.e. within or nearby KIF21B, TMEM39A and PRM1) along with the most significant SNPs from the original GWAS (or in the case of IL2RA where rs2104286 has been indicated as the primary association (6)) and from other subsequently identified MS susceptibility loci with varying levels of confidence. In addition, we examined the rank of these SNPs in a recent meta-analysis ( Table 3 ). The original P-values of the three newly identified loci were similar to those P-values seen in the other confirmed loci. Furthermore, each of these SNPs was mildly to moderately significant in the meta-analysis, but as in the initial GWAS follow-up, these loci fall far enough from the top that they are not initially selected for limited follow-up. It follows that there may be other yet-to-be-confirmed loci within this same range of the data. It is also noteworthy to highlight the robustness of the CMH test compared with the TDT in identifying all of these loci in the original screen. This may in part be related to the gain in power due to the additional samples used in the CMH analysis.
The new MS loci identified in this study are functionally interesting. KIF21B is a plus end-directed kinesin-like There is one SNP for which the dbSNP 'snp_id' was merged into a new 'rsID' since the publication of the original GWAS (previous rsID/current rsID). CHR, chromosome; A1, minor allele; A2, major allele; BP, physical base pair location of SNP in build 36; MAF, minor allele frequency; OR, odds ratio (relative to the minor allele); L95/U95, lower and upper bounds of the 95% confidence interval for the OR. Alleles are specified with respect to the forward (þ) strand of the National Center for Biotechnology Information's Build 36.
protein (KLP) involved in neuronal (axonal) transport. Its uniqueness stems from its enrichment in dendrites compared with the typical cell body and from its contrast from other plus end-directed KLPs, which have axon enrichment (16) . KIF21B is also expressed in a variety of immune cells. Although KIF21B has not been functionally associated with neurodegeneration or inflammation, given the nature and role of its protein in neurons, there is a plausible biologic role for this gene in MS. Recently, another kinesin superfamily member (KIF1B) was reported as associated with MS (17); however, efforts by the IMSGC have failed to confirm this association (IMSGC, unpublished data). KIF21B is among the first genes identified via association studies, with the potential for a direct neurodegenerative role in MS pathology. Very little has been known about TMEM39A (mRNAtransmembrane protein 39A). The associated SNP (rs1132200) within this gene causes a non-synonymous amino acid change (alanine-threonine) at position 487 in the protein. Although this SNP may hold some functional effect relevant to MS, almost nothing is known about this gene and what biologic role it might play with regard to disease susceptibility.
PRM1 (protamine 1) functions as a DNA-binding protein expressed in the nucleus of sperm. The strongest association in this region is with rs243315 and is 5 0 of PRM1; however, there are several SNPs across this region of chromosome 16 showing mild-to-moderate levels of significance within the top hits (rs12922090, rs243315, rs1292773) ( Table 2 ). This region of chromosome 16 is .100 kb from CLEC16A and there is little-to-no LD between these SNPs and any SNP within CLEC16A. There is, however, a very nearby candidate gene, SOCS1 (suppressor of cytokine signaling 1), which is in strong LD with these SNPs and could possibly contain the true association. Additional work is needed to explore the exact location of this association, and is the focus of ongoing laboratory efforts.
Through this exhaustive follow-up approach, we have identified a number of additional MS susceptibility loci and highlighted even more loci that may yet prove to be involved in MS. Ultimately, fine mapping and functional studies will be required to understand the consequences of the associations detected in this experiment.
MATERIALS AND METHODS
Case and control subjects
Stage 1 follow-up. DNA samples from study participants were ascertained at two sites within the USA [Brigham and Women's Hospital in Boston (BWH) and the University of California at San Francisco (UCSF)] and through one site in the UK [University of Cambridge (CMS)]. All affected individuals met the McDonald criteria for a positive diagnosis for MS (18) . Unrelated controls were obtained from these US sites and from the British 1958 Birth Cohort Study. These controls were selected to provide nearly equivalent gender and age matching. This sample set contained 2961 individuals (1479 cases and 1482 controls) for genotyping. Additional control sample data were available on 2198 samples from both the National Institute of Mental Health (NIMH) and the Wellcome Trust Case Control Consortium (WTCCC). Data from these additional controls were previously analyzed in the 110 SNPs selected for replication in the original GWAS (1) . With the exception of a small set of overlapping SNPs genotyped in this effort (95 of the 110 SNPs from the replication phase of the original GWAS were genotyped and analyzed in this study), these control data are completely independent of previous association testing in these MS samples. All samples used in the Stage 1 analysis come from participants self-reporting as non-Hispanic whites (Table 4) . These results are for rs767455 (only 367 base pairs from rs4149623) not for rs4149623 (as rs4149623 was not included in the meta-analysis data set).
Stage 2 follow-up. Cases and controls genotyped for Stage 2 were made available through an entirely independent replication set (11) . This data set consists of an additional 2164 cases and 2016 controls from the sites listed previously as well as those made available through other collaborative efforts. The same criteria were applied to these cases and controls as in Stage 1 (Table 5) . Approval for these studies was granted by the appropriate institutional review boards. All studies were performed after informed consent from human subjects.
Molecular analysis
Stage 1 follow-up. We utilized the Illumina iSelect Custom BeadChip platform to perform additional genotyping of a more in-depth list of top hits from the GWAS experiment (19) . This experiment was performed in parallel with several These control data were provided by both the NIMH and the WTCCC and represent the 723 US controls and the 1475 UK controls (respectively) used in the 110 SNP replication analysis of our original screen (1). Figure S2 provides a visual summary of those SNPs analyzed in Stage 1 relative to their significance in the original GWAS and of those SNPs further chosen and analyzed in Stage 2.
We followed the Illumina Infinium protocol for the genotyping of DNA samples. In brief, this involved amplification and subsequent fragmentation of genomic DNA, followed by hybridization of this fragmented DNA to the BeadChip, then an extension step and finally imaging to read the chip (19) . We genotyped an initial data set of 2961 individuals (1479 cases and 1482 controls) distributing DNA samples across beadchips (12 samples per beadchip), with attention given to representing both cases and controls from each of the different ascertainment sites on every chip as to minimize any experimental biases in genotyping performance.
Stage 2 follow-up. Following the analysis for Stage 1, there were 85 SNPs outside of the MHC region with association P-values 0.001, and of these, we genotyped 20 SNPs in a second independent data set (independent of both Stage 1 and the original GWAS) for our Stage 2 follow-up. There were five criteria used to select the SNPs for Stage 2 genotyping: (i) Stage 1 P-value 0.001; (ii) SNPs within or nearby known genes; (iii) exclusion of SNPs in the MHC (within 29-34 Mb on chromosome 6); (iv) exclusion of SNPs overlapping with previously identified MS genes or examined as part of the initial GWAS replication effort; (v) exclusion of SNPs being analyzed as part of other parallel projects using this common data set. We chose 21 SNPs that met these criteria; however, one SNP (rs9855065) failed to pass the design process. We used the Sequenom MassARRAY iPLEX platform for this genotyping. The Sequenom protocol involves a multiplex PCR reaction prior to a single-base primer extension reaction. The individual SNPs are identified by using matrixassisted laser desorption/ionization time-of-flight mass spectrometry (20) .
Statistical analysis
Stage 1 follow-up. We initially performed a thorough series of QC procedures, which are described in the Supplemental Material. Following stringent QC and finding no significant population differences in this data set, we chose to analyze this data set as one uniform sample collection ( Supplementary  Material, Fig. S3 ). The Stage 1 test for association was conducted using a logistic regression approach as implemented in PLINK and using PCA1 and PCA2 as covariates to correct for differential genotyping bias (21) . This method tests for a linear trend in the number of alleles at a single locus. This analysis included GWAS data from 2198 NIMH and WTCCC controls used in the original GWAS replication in addition to the newly genotyped data set of 1343 cases and 1379 controls. After removing SNPs from the MHC (i.e. 29-34 Mb on chromosome 6), the genomic inflation factor (GIF) was 1.16 ( Supplementary Material, Fig. S4 ). This is larger than the original GWAS GIF (1.05) and is likely due to preferential selection of SNPs with small P-values. In addition to the standard logistic regression, a conditional logistic regression analysis was also performed conditioning on the HLA-DRB1
Ã 1501 tag SNP (rs3135388). Genotypes for rs3135388 had previously been imputed for the NIMH and WTCCC control, as this SNP was not genotyped on the Affymetrix 500K chip.
Stage 2 follow-up. PLINK was also used for the Stage 2 replication analysis. Logistic regression was used to test for association with the 19 SNPs and 4180 independent replication samples that passed QC. To perform a joint analysis of both Stage 1 and Stage 2 data sets, and the original GWAS screen (931 trios and 2431 controls), the UNPHASED software was utilized (22) . A joint conditional analysis was also done on the HLA-tag SNP (rs3135388) in UNPHASED.
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